BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15459307)

  • 1. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
    Klastersky J
    N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
    [No Abstract]   [Full Text] [Related]  

  • 2. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 3. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Marty FM; Lowry CM
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
    [No Abstract]   [Full Text] [Related]  

  • 4. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Schneemann M; Imhof A
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
    [No Abstract]   [Full Text] [Related]  

  • 8. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 9. Modern antifungal therapy for neutropenic fever.
    Corey M
    Curr Hematol Malig Rep; 2006 Jun; 1(2):95-100. PubMed ID: 20425338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Jones BL; McLintock LA
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
    [No Abstract]   [Full Text] [Related]  

  • 11. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
    Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
    J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
    [No Abstract]   [Full Text] [Related]  

  • 12. [The future of antifungal agents].
    Maesaki S
    Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: caspofungin acetate for treatment of invasive fungal infections.
    Chan J
    Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
    [No Abstract]   [Full Text] [Related]  

  • 14. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Ullmann AJ; Heussel CP; Cornely OA
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
    Sims-McCallum RP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986
    [No Abstract]   [Full Text] [Related]  

  • 17. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on antifungal therapy.
    Gigolashvili T
    Cancer Pract; 1999; 7(3):157-9. PubMed ID: 10352080
    [No Abstract]   [Full Text] [Related]  

  • 19. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Johnson JR
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12037157
    [No Abstract]   [Full Text] [Related]  

  • 20. Voriconazole for candidosis: an important addition?
    Graybill JR
    Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.